Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926237 · ClinicalTrials.gov registry record · NA
Effect of rTMS on Resting State Brain Activity in Tinnitus
A NA study of Tinnitus, sponsored by University of Arkansas.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT00926237: Completed NA study of Tinnitus, sponsored by University of Arkansas.
NCT00926237 is a NA study of Tinnitus that has completed, run by University of Arkansas. The registered enrollment target is 58 participants, below the 12,617-participant average among 24 other Tinnitus trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00926237, a NA study of Tinnitus, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
One out of every five people experiences tinnitus (a ringing, buzzing, or roaring sound in the ear) ranging from mild to severe impairment. To date, there are no effective therapies available that have been shown to decrease tinnitus awareness. The purpose of this study is to evaluate a treatment option for tinnitus that uses a technique called Repetitive Transcranial Magnetic Stimulation (rTMS), which could prove to be an effective means of alleviating or reducing the symptoms of tinnitus.
Primary Outcome
Change from baseline on the daily analogue rating of tinnitus awareness. Analogue ratings are a validated self report instrument assessing subjects awareness of tinnitus in daily life. Possible scores range from 0 (no tinnitus) to 100 (painfully loud tinnitus). Change equals the average rating for a given treatment week or washout period minus the average rating over three baseline assessments.
Conditions Studied
Interventions
- DEVICE Sham rTMS - Sham repetitive transcranial magnetic stimulation
- DEVICE Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency
- DEVICE Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-01 |
| Est. Completion | 2019-09 |
| Phase | NA |
What the finished NCT00926237 record still lists
NCT00926237 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 12,617-participant average among 24 other Tinnitus trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Tinnitus appearing as the primary indexed condition, and to 3 interventions - of which Sham rTMS - Sham repetitive transcranial magnetic stimulation is the first listed.
NCT00926237 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00926237 about?
NCT00926237 is a clinical study titled "Effect of rTMS on Resting State Brain Activity in Tinnitus". One out of every five people experiences tinnitus (a ringing, buzzing, or roaring sound in the ear) ranging from mild to severe impairment. To date, there are no effective therapies available that have been shown to decrease tinnitus awareness. The purpose of this study is to evaluate a treatment op...
What is the current status of trial NCT00926237?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2009-01. Estimated completion is 2019-09.
What conditions does trial NCT00926237 study?
This clinical trial studies the following conditions: Tinnitus.
What interventions are being tested in trial NCT00926237?
The interventions under investigation include: Sham rTMS - Sham repetitive transcranial magnetic stimulation (DEVICE), Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency (DEVICE), Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency (DEVICE).
Who is sponsoring clinical trial NCT00926237?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00926237 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinnitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00926237's enrollment target sits among peer trials
58 16th of 24 higher than 9 of 24 other Tinnitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tinnitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment for PTSD and Tinnitus
RECRUITING · NA
-
Investigating EEG as a Biomarker for Tinnitus Improvement After Bimodal Stimulation
RECRUITING · NA
-
Somatosensory Tinnitus RCT
RECRUITING · NA
-
Noninvasive Therapy for Tinnitus
RECRUITING · NA
-
External Therapy for Tinnitus Management
RECRUITING · NA
-
Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia